Article Information
History
- May 5, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Xabier Michelena1,2,
- Helena Borrell1,
- Mireia López-Corbeto1,
- María López-Lasanta1,
- Estefanía Moreno1,
- María Pascual-Pastor1,
- Alba Erra1,
- Mayte Serrat1,
- Esther Espartal1,
- Susana Antón1,
- Gustavo Adolfo Añez1,
- Raquel Caparrós-Ruiz1,
- Andrea Pluma1,
- Ernesto Trallero-Araguás1,
- Mireia Barceló-Bru1,
- Miriam Almirall1,
- Juan José De Agustín1,
- Jordi Lladós Segura1,
- Antonio Julià1 and
- Sara Marsal1,*
- 1Rheumatology Department, Rheumatology Research Group, Vall d’Hebron Research Institute, Vall d’Hebron University Hospital, Barcelona, Spain
- 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
- ↵*Corresponding author:
Sara Marsal, Rheumatology Department, Vall d’Hebron University Hospital, Barcelona, Spain. Email: sara.marsal{at}vhir.org. Tel: +34 934896604.
Posted May 05, 2020.
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
